An observational study «FOLLITROPIN» comparing the efficacy of follitropin alpha biosimilar: the real-world data

• Váldodahkkit: D. P. Kamilova (Dahkki), M. M. Ovchinnikova (Dahkki), E. Sh. Ablyaeva (Dahkki), M. M. Leviashvili (Dahkki), N. S. Stuleva (Dahkki), E. V. Broitman (Dahkki), M. A. Ganikhina (Dahkki), E. N. Mayasina (Dahkki), L. F. Iskhakova (Dahkki), K. Yu. Boyarskiy (Dahkki), E. N. Ovsyannikova (Dahkki), Z. B. Barakhoeva (Dahkki), S. V. Nikitin (Dahkki), I. A. Bendusov (Dahkki), Yu. A. Fetisova (Dahkki), M. A. Yudina (Dahkki), E. S. Tararashkina (Dahkki), D. T. Khetagurova (Dahkki), D. V. Blinov (Dahkki), M. A. Polzikov (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: IRBIS LLC, 2021-03-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Introduction. The efficacy and safety of biosimilar follitropin alpha have been demonstrated in randomized blinded prospective clinical trials of phases I and III. Unfortunately, there is a gap between the clinical trials and real clinical practice data. The real-world patient data helps to create a...